STOCK TITAN
  1. Home
  2. News
  3. ABVC

Abvc Biopharma Inc - ABVC STOCK NEWS

Welcome to our dedicated page for Abvc Biopharma news (Ticker: ABVC), a resource for investors and traders seeking the latest updates and insights on Abvc Biopharma stock.

ABVC BioPharma Inc (ABVC) is a clinical-stage biopharmaceutical company developing novel therapies for oncology, neurology, and ophthalmology using botanically derived formulations. This page serves as the definitive source for ABVC-related news, offering stakeholders timely updates on clinical progress and corporate developments.

Investors and researchers will find curated press releases covering Phase II clinical trials, regulatory milestones, and strategic partnerships with leading institutions. Our collection includes updates on drug pipeline advancements, intellectual property achievements, and operational efficiency initiatives that characterize ABVC BioPharma's approach.

Key updates focus on therapeutic candidates for triple-negative breast cancer, ADHD treatments, and ophthalmologic devices, alongside financial disclosures and collaboration announcements. All content is verified for accuracy and relevance to support informed decision-making.

Bookmark this page for streamlined access to ABVC's latest developments in botanical drug innovation and clinical-stage progress. Check regularly for authoritative updates on this pioneering biopharmaceutical enterprise.

News

ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine

Rhea-AI Summary
ABVC BioPharma, Inc. CEO Dr. Uttam Patil recognized as a Top 10 CEO in Taiwan 2024 for his exceptional leadership and contributions. The Company has seen a rise in stock price, international growth, and success under his guidance. Dr. Patil's focus on innovation, sustainable practices, and community engagement reflects his commitment to excellence and long-term shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
none
-
News

ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update

Rhea-AI Summary
ABVC BioPharma, Inc. announces 2023 financial results, strategic investments, licensing deals, and operational highlights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
earnings
-
News

ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars

Rhea-AI Summary
ABVC BioPharma, Inc. provides an update on the development of combination therapy for cancer and immunity booster dietary supplements derived from Maitake Mushroom. The company is marketing supplements and pursuing clinical trials of pharmaceutical compounds approved by the US FDA. BioKey, the company's subsidiary, is working on the manufacturing and distribution of these products, aiming to tap into the growing global markets for cancer therapeutics, dietary supplements, and pharmaceutical CDMO services.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
none
News

ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues

Rhea-AI Summary
ABVC BioPharma, Inc. (NASDAQ: ABVC) signs a definitive agreement to license its healthcare-related expertise to Senior Paradise, Inc. for further development in the healthcare industry. The agreement includes leasing the Company's properties for projects such as a long-term care center and plant factories. SPI will pay ABVC $3M as a license fee and 2% royalties on revenues. The strategic partnership aims to maximize the value of ABVC's resources and potentially create a new revenue stream.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.59%
Tags
none
-
News

ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)

Rhea-AI Summary
ABVC BioPharma, Inc. (NASDAQ: ABVC) secures Australian patent for PDC-1421 extract for Major Depressive Disorder treatment until 2040. The Company's asset ABV-1504, a botanical-based NET inhibitor, completes Phase II studies for MDD. ABVC enters global licensing agreement with AiBtl BioPharma Inc. for CNS drugs, expecting significant revenue potential.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
none
-
News

ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share

Rhea-AI Summary
ABVC BioPharma, Inc. has signed a definitive agreement to acquire real estate in Taoyuan City, Taiwan, estimated at approximately $2.96 million. The acquisition aims to develop plant factories for ABVC’s botanical pipeline and establish a base for Good Agricultural Practices fields. The company will issue shares of common stock and a warrant to purchase up to 1,000,000 shares of common stock in consideration for ownership of the property. The acquisition is expected to raise shareholders' equity and facilitate ABVC’s drug development plan, generating future revenue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
acquisition
News

ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees

Rhea-AI Summary
ABVC BioPharma, Inc. (NASDAQ: ABVC) and its subsidiary BioLite, Inc. announced that they received 46 million shares from AiBtl BioPharma Inc. as the first milestone payment under a global licensing agreement. The agreement values the payment at $460. The Company's pipeline of products has excellent market potential, with the MDD market expected to reach $14.96 billion by 2032 and the global ADHD treatment market expected to grow at a CAGR of 7.3% between 2023-2032.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
60.83%
Tags
none
-
News

ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study

Rhea-AI Summary
ABVC BioPharma, Inc. (NASDAQ: ABVC) provided an update on the eight-week long ADHD Phase II part II clinical study at the University of California San Francisco Medical Center and five Taiwanese medical centers. Out of 94 screened subjects, 69 enrolled, and 60 completed the study. The Phase II part I clinical study successfully achieved primary endpoints and was accepted by the FDA. The CEO expects positive results in the interim analysis report and plans to continue the study by enrolling another thirty patients. The global ADHD treatment market is projected to reach $32.14 billion by 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.41%
Tags
clinical trial
-
News

ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical Trials

Rhea-AI Summary
ABVC BioPharma, Inc. (ABVC) shared an interview with Dr. Scott Irwin, MD, Ph.D., the Principal Investigator for the clinical trials of ABV-1601, the Company’s drug under development to treat depression in cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
clinical trial
News

ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market

Rhea-AI Summary
ABVC BioPharma, Inc. (ABVC) announced the receipt of a U.S. patent for PDC-1421, a Radix Polygala extract used in their asset ABV-1505 targeting ADHD. The patent grants exclusivity until 2040. ABVC is awaiting patent applications in the EU, China, and Japan. ABV-1505, a botanical-based NET inhibitor, is in Phase IIb clinical studies for ADHD treatment. The global ADHD treatment market is projected to reach $32.14 billion by 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.33%
Tags
none
Stock ABVC logo
Abvc Biopharma Inc

Nasdaq:ABVC

ABVC Rankings

#2860 Ranked by Market Cap
N/A Ranked by Dividends

ABVC Stock Data

13.49M
10.13M
21.95%
3.89%
1.76%
Biotechnology
Pharmaceutical Preparations
Link
United States
FREMONT